Log in

NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, Forecast & News

$5.61
-0.14 (-2.43 %)
(As of 02/17/2020 02:42 AM ET)
Add
Today's Range
$5.48
Now: $5.61
$5.79
50-Day Range
$3.67
MA: $5.15
$6.01
52-Week Range
$3.35
Now: $5.61
$12.57
Volume321,493 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:ADMS
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees159
Next Earnings Date3/2/2020 (Estimated)
OptionableOptionable

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.


Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) issued its quarterly earnings data on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by $0.09. The specialty pharmaceutical company earned $13.93 million during the quarter, compared to analyst estimates of $14.36 million. View Adamas Pharmaceuticals' Earnings History.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Adamas Pharmaceuticals.

What guidance has Adamas Pharmaceuticals issued on next quarter's earnings?

Adamas Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Wednesday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.6-54.6 million, compared to the consensus revenue estimate of $53.65 million.

What price target have analysts set for ADMS?

10 analysts have issued 12 month target prices for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' share price to reach $15.67 in the next twelve months. This suggests a possible upside of 179.3% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.

What is the consensus analysts' recommendation for Adamas Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.

Has Adamas Pharmaceuticals been receiving favorable news coverage?

News coverage about ADMS stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Adamas Pharmaceuticals.

Are investors shorting Adamas Pharmaceuticals?

Adamas Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,380,000 shares, an increase of 28.6% from the December 31st total of 1,850,000 shares. Based on an average daily trading volume, of 641,000 shares, the days-to-cover ratio is currently 3.7 days. Currently, 10.7% of the shares of the company are sold short. View Adamas Pharmaceuticals' Current Options Chain.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Agile Therapeutics (AGRX), Amarin (AMRN), Sangamo Therapeutics (SGMO), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL) and Abeona Therapeutics (ABEO).

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the folowing people:
  • Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)
  • Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)
  • Ashleigh Barreto, Director of Corp. Communications & Investor Relations
  • Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Emerald Advisers LLC (2.26%), Emerald Mutual Fund Advisers Trust (2.00%), State Street Corp (1.51%), Deltec Asset Management LLC (1.43%), Panagora Asset Management Inc. (1.08%) and Renaissance Technologies LLC (1.05%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Institutional Ownership Trends for Adamas Pharmaceuticals.

Which institutional investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Emerald Mutual Fund Advisers Trust, Jane Street Group LLC, Emerald Advisers LLC and Bank of New York Mellon Corp. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went and Jennifer J Rhodes. View Insider Buying and Selling for Adamas Pharmaceuticals.

Which institutional investors are buying Adamas Pharmaceuticals stock?

ADMS stock was bought by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Renaissance Technologies LLC, DCF Advisers LLC, Virtu Financial LLC, Jacobs Levy Equity Management Inc., AQR Capital Management LLC, Oxford Asset Management LLP and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Adamas Pharmaceuticals.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $5.61.


MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  375 (Vote Outperform)
Underperform Votes:  311 (Vote Underperform)
Total Votes:  686
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: What is a back-end load?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel